查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1736432

全球甲状腺疾病治疗市场规模（按药物类型、疾病、给药途径、地区和预测）

Global Thyroid Disorder Treatment Market Size By Drug Type (Levothyroxine, Liothyronine, Propylthiouracil), By Disease (Hypothyroidism, Hyperthyroidism), By Route Of Administration (Oral, Intravenous), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

甲状腺疾病治疗市场规模及预测

2024 年甲状腺疾病治疗市场规模价值 22 亿美元，预计到 2032 年将达到 28 亿美元，2026 年至 2032 年的复合年增长率为 3.17%。

  • 甲状腺疾病的治疗包括使用甲状腺机能低下症等疾病。这些治疗旨在恢復甲状腺激素水平并缓解症状。
  • 目前，甲状腺功能亢进和甲状腺机能低下症分别采用放射性碘和甲状腺荷尔蒙补充疗法治疗。严重病例也可考虑手术治疗。定期监测可确保有效治疗。
  • 未来，个体化医疗、标靶治疗和基因编辑的进步可能成为治疗的核心。新药有可能改善疗效，提供更精准的治疗，同时最大限度地减少副作用。

全球甲状腺疾病治疗市场动态

影响全球甲状腺治疗市场的关键市场动态是：

关键市场驱动因素

  • 发病率不断上升：甲状腺甲状腺机能低下症和甲状腺功能亢进症等甲状腺疾病的发病率正在上升，随着检测和认识的提高，对更好的治疗方法的需求也日益增加。
  • 治疗进步：改进配方和个人化治疗等药物创新将提高治疗的有效性和吸引力，从而推动市场成长。
  • 人口老化：老年人患甲状腺疾病的可能性不断增加，这推动了对适合治疗与老龄化相关的甲状腺疾病的替代疗法的需求。
  • 获得医疗保健：改善新兴经济体的医疗保健基础设施和获得医疗保健的机会将增加诊断和治疗的可用性，从而推动这个以前被忽视的领域的市场成长。

主要问题

  • 缺乏认识：对甲状腺疾病的知识和教育不足可能会导致诊断和治疗的延迟，从而降低市场潜力。
  • 有限的访问：农村和服务不足地区的医疗保健基础设施不足可能会阻碍诊断和治疗，从而限制市场成长。
  • 副作用与问题：与甲状腺疾病治疗相关的副作用和问题可能会导致患者违规并降低整体市场接受度。

主要趋势

  • 先进的诊断：先进的诊断设备和影像技术的进步使得能够早期准确地发现甲状腺疾病。
  • 生技药品和标靶治疗：生技药品和标靶治疗的开发和实施为解决甲状腺疾病的根本原因提供了新的治疗方法选择。
  • 远端医疗位健康：远端医疗和数位健康技术越来越多地用于远端监控和远端系统管理，改善患者获得护理的机会和依从性。

目录

第一章全球甲状腺疾病治疗市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球甲状腺疾病治疗市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球甲状腺疾病治疗市场（依药物类型）

  • 概述
  • 左甲状腺素
  • 三碘甲状腺胺酸
  • 丙硫氧嘧啶
  • 咪唑化合物
  • β阻断剂

6. 全球甲状腺疾病治疗市场（依疾病类型）

  • 概述
  • 甲状腺机能低下症
  • 甲状腺功能亢进

7. 全球甲状腺治疗市场（依最终用户）

  • 概述
  • 口服
  • 静脉注射

8. 全球甲状腺治疗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

9. 全球甲状腺治疗市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第十章 公司简介

  • AbbVie, Inc.
  • Mylan NV
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Abbott Laboratories
  • Allergan plc
  • Bayer AG
  • Novartis AG
  • Sanofi SA
  • GlaxoSmithKline plc.

第十一章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十二章 附录

  • 相关调查
简介目录
Product Code: 36370

Thyroid Disorder Treatment Market Size And Forecast

Thyroid Disorder Treatment Market size was valued at USD 2.2 Billion in 2024 and is projected to reach USD 2.8 Billion by 2032 growing at a CAGR of 3.17% from 2026 to 2032.

  • Thyroid disorder treatment is controlling conditions such as hypothyroidism and hyperthyroidism using medications such as levothyroxine or antithyroid agents. These treatments are intended to restore thyroid hormone levels and reduce symptoms.
  • Radioactive iodine and thyroid hormone replacement therapy are currently used to treat hyperthyroidism and hypothyroidism, respectively. Surgery may be considered in severe situations. Regular monitoring enables efficient management.
  • In the future, treatments may center on customized medicine, targeted therapeutics and advances in gene editing. Emerging medicines may provide more precise management, improving outcomes while minimizing side effects.

Global Thyroid Disorder Treatment Market Dynamics

The key market dynamics that are shaping the global Thyroid Disorder Treatment Market include:

Key Market Drivers:

  • Increasing Incidence: Rising occurrences of thyroid problems, including as hypothyroidism and hyperthyroidism, are driving need for better therapies, aided by increasing detection rates and awareness.
  • Advancements in Treatment: Pharmaceutical innovations, such as improved medication formulations and tailored therapies, improve treatment efficacy and appeal, promoting market growth.
  • Aging Population: The expanding older population, which is more prone to thyroid problems, adds to the demand for therapeutic alternatives suited to age-related thyroid conditions.
  • Healthcare Access: Increasing healthcare infrastructure and access in emerging countries increases diagnostic and treatment availability, boosting market growth in previously neglected areas.

Key Challenges:

  • Lack of Awareness: Inadequate knowledge and education about thyroid problems might result in delayed diagnosis and treatment, diminishing market potential.
  • Limited Access: Inadequate healthcare infrastructure in rural or disadvantaged areas might impede diagnosis and treatment, limiting market growth.
  • Adverse Effects and Problems: Treatment side effects and problems from thyroid disorders might lead to patient noncompliance and reduce overall market acceptance.

Key Trends:

  • Advanced Diagnostics: Improvements in advanced diagnostic instruments and imaging techniques have resulted in earlier and more accurate detection of thyroid problems.
  • Biologics and Targeted Therapies: The development and implementation of biologic medications and targeted therapies to address the underlying causes of thyroid problems, hence providing new therapeutic choices.
  • Telemedicine and Digital Health: Telemedicine and digital health technologies are increasingly being used for remote monitoring and management, hence enhancing patient access to care and treatment adherence.

Global Thyroid Disorder Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global Thyroid Disorder Treatment Market:

North America:

  • According to Verified Market Research, North America is expected to dominate the global Thyroid Disorder Treatment Market.
  • North America is likely to lead the worldwide thyroid disease treatment market due to its sophisticated healthcare infrastructure, high prevalence of thyroid disorders and major expenditure in R&D.
  • The region's strong medical facilities and high levels of awareness help to maintain its leadership position, which is reinforced by ongoing advancements in treatment and diagnostics.

Asia Pacific:

  • According to Verified Market Research, Asia Pacific is fastest growing region in global Thyroid Disorder Treatment Market.
  • Asia-Pacific is the fastest-growing area in the worldwide thyroid disease treatment market, due to growing healthcare investments, rising thyroid condition prevalence and greater access to modern medical technologies. The region's high economic growth and improved healthcare facilities help to boost market expansion.

Global Thyroid Disorder Treatment Market: Segmentation Analysis

The Global Thyroid Disorder Treatment Market is segmented on the basis of Drug Type, Disease, Route of Administration, and Geography.

Thyroid Disorder Treatment Market, By Drug Type

  • Levothyroxine
  • Liothyronine
  • Propylthiouracil
  • Imidazole-based Compounds
  • Beta-blockers

Based on Drug Type, The market is segmented into Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based Compounds, Beta-blockers. Levothyroxine is the most common drug type in the global thyroid disease treatment market, used to treat hypothyroidism and maintain normal thyroid hormone levels.

Thyroid Disorder Treatment Market, By Disease

  • Hypothyroidism
  • Hyperthyroidism

Based on Disease, The market is segmented into Hypothyroidism and Hyperthyroidism. Hypothyroidism dominates the worldwide thyroid problem treatment market due to its higher prevalence than hyperthyroidism. The requirement for lifelong hormone replacement therapy creates increasing market demand and treatment possibilities.

Thyroid Disorder Treatment Market, By End-User

  • Oral
  • Intravenous

Based on End-User, The market is segmented into Oral and Intravenous. The oral category leads the global thyroid disease therapy market due to its convenience, ease of administration and patient preference. Oral medicines are commonly used to treat thyroid problems.

Key Players

The "Global Thyroid Disorder Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are AbbVie, Inc., Mylan N.V., Merck & Co., Inc., Pfizer, Inc., Abbott Laboratories, Allergan plc, Bayer AG, Novartis AG, Sanofi S.A., GlaxoSmithKline plc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

  • Global Thyroid Disorder Treatment Market Recent Developments
  • In December 2023, Aspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings Limited, reached an agreement with Sandoz AG to acquire its Chinese business. This strategic move was consistent with Aspen's strategy goal of increasing its footprint in China by using Sandoz's proven portfolio, infrastructure and experienced team for future growth in the region.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL THYROID DISORDER TREATMENT MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL THYROID DISORDER TREATMENT MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL THYROID DISORDER TREATMENT MARKET, BY DRUG TYPE

  • 5.1 Overview
  • 5.2 Levothyroxine
  • 5.3 Liothyronine
  • 5.4 Propylthiouracil
  • 5.5 Imidazole-based Compounds
  • 5.6 Beta-blockers

6 GLOBAL THYROID DISORDER TREATMENT MARKET, BY DISEASE

  • 6.1 Overview
  • 6.2 Hypothyroidism
  • 6.3 Hyperthyroidism

7 GLOBAL THYROID DISORDER TREATMENT MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Oral
  • 7.3 Intravenous

8 GLOBAL THYROID DISORDER TREATMENT MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL THYROID DISORDER TREATMENT MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 AbbVie, Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Mylan N.V.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Merck & Co., Inc.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Pfizer, Inc.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Abbott Laboratories
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Allergan plc
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Bayer AG
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Novartis AG
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Sanofi S.A.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 GlaxoSmithKline plc.
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research